Ilomedin

Iloprost trometamol, the active ingredient in Ilomedin, is a prostacyclin analog presented as an injectable solution for intravenous use. It is indicated for the treatment of pulmonary arterial hypertension and for digital ulcers associated with systemic sclerosis in adult patients. GNH USA supplies Ilomedin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ilomedin is a prostacyclin analog used in the management of vascular disorders affecting the pulmonary circulation and skin microvasculature.

Pulmonary arterial hypertension: improves exercise capacity and reduces pulmonary vascular resistance. Digital ulcers associated with systemic sclerosis: promotes ulcer healing and reduces the formation of new ulcers.

Ilomedin may cause a range of adverse reactions, most of which are related to its vasodilatory activity.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Nausea: occasional gastrointestinal upset. - Jaw pain: discomfort during chewing.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical intervention. - Pulmonary edema: accumulation of fluid in the lungs. - Bleeding complications: increased risk of hemorrhage, especially when combined with anticoagulants.

Before initiating Ilomedin therapy, clinicians should consider several safety measures.

Monitor blood pressure: check regularly due to potent vasodilatory effect. Assess bleeding risk: avoid in patients with active hemorrhage or uncontrolled coagulopathy. Evaluate renal function: adjust therapy if significant impairment is present. Avoid concurrent prostacyclin analogs: combined use may amplify adverse effects. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ilomedin can interact with other medications that influence vascular tone or coagulation.

Major Interactions (Avoid): - Concomitant nitrates or other vasodilators: may cause severe hypotension. - Anticoagulants (e.g., warfarin, heparin): increased risk of bleeding. - Phosphodiesterase inhibitors: potentiation of vasodilatory response.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs: may affect renal function. - Calcium channel blockers: additive hypotensive effect. - Beta‑blockers: may mask tachycardia associated with vasodilation.